FOGHORN THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.51 USD | -5.16% |
|
-0.90% | -14.57% |
| May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 721.4 | 848.3 | 266.7 | 272.3 | 234.6 | - | - |
| Enterprise Value (EV) 1 | 555.3 | 805.5 | -79.1 | 272.3 | 88.26 | -97.38 | 34.24 |
| P/E ratio | -3.25 x | -8.38 x | -2.44 x | -2.76 x | -2.57 x | -3.49 x | -3.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,678 x | 643 x | 13.9 x | 7.97 x | 9.89 x | 6.89 x | 6.2 x |
| EV / Revenue | 1,291 x | 611 x | -4.11 x | 7.97 x | 3.72 x | -2.86 x | 0.9 x |
| EV / EBITDA | -8.26 x | -8.26 x | 0.69 x | -2.61 x | -0.68 x | 0.77 x | -0.21 x |
| EV / FCF | - | -15 x | -0.41 x | - | -0.78 x | 0.78 x | -0.3 x |
| FCF Yield | - | -6.65% | -243% | - | -128% | 128% | -335% |
| Price to Book | 5.1 x | 9.75 x | 2,363 x | - | -30.6 x | -3.51 x | - |
| Nbr of stocks (in thousands) | 35,591 | 37,093 | 41,802 | 42,217 | 42,586 | - | - |
| Reference price 2 | 20.27 | 22.87 | 6.380 | 6.450 | 5.510 | 5.510 | 5.510 |
| Announcement Date | 3/18/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.43 | 1.319 | 19.23 | 34.16 | 23.72 | 34.03 | 37.86 |
| EBITDA 1 | - | -67.2 | -97.51 | -113.8 | -104.5 | -130.7 | -125.9 | -164 |
| EBIT 1 | - | -68.53 | -100.7 | -117.1 | -107.9 | -119.3 | -122.4 | -124.5 |
| Operating Margin | - | -15,937.44% | -7,637.15% | -609.2% | -315.93% | -502.86% | -359.54% | -328.8% |
| Earnings before Tax (EBT) 1 | - | -68.8 | -101.3 | -108.9 | -94.2 | -108 | -104.9 | -114.2 |
| Net income 1 | -51.13 | -68.8 | -101.3 | -108.9 | -98.43 | -108.2 | -110 | -115.6 |
| Net margin | - | -16,000% | -7,681.58% | -566.27% | -288.17% | -456.19% | -323.23% | -305.49% |
| EPS 2 | -1.410 | -6.230 | -2.730 | -2.620 | -2.340 | -2.145 | -1.578 | -1.450 |
| Free Cash Flow 1 | - | - | -53.56 | 192.4 | - | -113 | -125.1 | -114.5 |
| FCF margin | - | - | -4,060.88% | 1,000.63% | - | -476.57% | -367.55% | -302.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/2/20 | 3/18/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.713 | 3.92 | 4.49 | 6.634 | 4.184 | 5.309 | 5.599 | 17.48 | 5.769 | 5.05 | 6.726 | 6.814 | 7.574 | 9.5 | 9.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -28.08 | -27.8 | -29.19 | -28.26 | -31.89 | -33.32 | -32.05 | -17.08 | -25.46 | -28.19 | -30.17 | -30.49 | -30.17 | - | - |
| Operating Margin | -3,938.57% | -709.29% | -650.07% | -425.97% | -762.09% | -627.56% | -572.42% | -97.73% | -441.29% | -558.3% | -448.62% | -447.48% | -398.33% | - | - |
| Earnings before Tax (EBT) 1 | -29.14 | -26.91 | -27.31 | -25.77 | -28.89 | -29.93 | -28.54 | -13.61 | -22.12 | -25.02 | -22.07 | -22.34 | -21.46 | - | - |
| Net income 1 | -29.14 | -26.91 | -27.31 | -25.77 | -28.89 | -30.49 | -29.49 | -14.34 | -24.11 | -25.02 | -24.23 | -25.11 | -25.43 | - | - |
| Net margin | -4,087.38% | -686.58% | -608.31% | -388.44% | -690.39% | -574.27% | -526.65% | -82.07% | -417.85% | -495.37% | -360.3% | -368.43% | -335.76% | - | - |
| EPS 2 | -0.7700 | -0.6500 | -0.6600 | -0.6200 | -0.6900 | -0.7300 | -0.7000 | -0.3400 | -0.5700 | -0.5900 | -0.6550 | -0.5000 | -0.4575 | -0.3600 | -0.3700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/9/23 | 5/8/23 | 8/4/23 | 11/2/23 | 3/7/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 166 | 42.8 | 346 | - | 146 | 332 | 200 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -53.6 | 192 | - | -113 | -125 | -115 |
| ROE (net income / shareholders' equity) | - | - | -83.4% | -225% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 3.970 | 2.350 | 0 | - | -0.1800 | -1.570 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | 3.31 | 1.21 | - | 4.41 | 4.85 | 3.92 |
| Capex / Sales | - | - | 251.18% | 6.29% | - | 18.59% | 14.25% | 10.35% |
| Announcement Date | 10/2/20 | 3/18/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.51
USD
Average target price
11.67
USD
Spread / Average Target
+111.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.57% | 235M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- FHTX Stock
- Financials Foghorn Therapeutics Inc.
